• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    CNS spectrums

    CNS spectrums

    JournalISSN 1092-8529eISSN 2165-6509中科院 医学 3区

    年发文量

    研究主题

    论文(4514)

    排序
    1Global Divergence of Stroke and Major Depressive Disorder: Unveiling a Potential “hidden Stagnation” Pattern Through an Integrated Medicine Perspective
    Kui Jia, Ling-Ling Qian,Fu-Cheng Zhao, Qian Sun,Meng-Meng Zhang, Yi-Fan Li

    Abstract Background Major depressive disorder (MDD) is associated with increased stroke risk and can be conceptualized in Traditional Chinese Medicine (TCM) as emotional constraint or “Qi Stagnation” that may contribute to “Blood Stasis.” However, the country-level ecological relationship between stroke burden and MDD prevalence remains unclear, and high-stroke settings may have under-recognized MDD because of differences in data availability, diagnostic practices, mental health services, and cultural symptom expression. This study quantifies this ecological association and interprets it through an Integrated Medicine framework. Methods Using Global Burden of Disease (GBD) 2023 data, we analyzed age-standardized stroke Disability-Adjusted Life Year (DALY) rates for all stroke and age-standardized prevalence rates for the GBD cause category of MDD across 204 countries and territories from 1990 to 2023. An exploratory Diagnostic Gap Score (ZStroke—ZMDD) was developed to identify countries and territories with disproportionate stroke burden relative to reported MDD prevalence. Results A negative ecological correlation emerged globally and strengthened over time ( r = −0.059 in 1990 versus r = −0.218 in 2023, P = 0.002). The highest stroke burden quartile (Q4) reported lower MDD prevalence (2639.9/100 000) than the lowest quartile (3067.0/100 000; mean difference 427.1/100 000, 95% CI: 121.52 to 732.58), despite an 8.3% increase in stroke burden in Q4. The score identified clusters with disproportionate stroke burden relative to MDD prevalence in Eastern Europe, Southeast Asia, and Pacific Island settings. Conclusions Low reported MDD prevalence in high-stroke countries and territories suggests a potential diagnostic, reporting, or data-quality mismatch rather than biological protection. These ecological findings do not prove that undiagnosed MDD causes stroke burden, but they support culturally adapted mental health screening in primary care, stroke-prevention clinics, and community health settings, with referral pathways for those who screen positive.

    2026
    引用
    AI阅读
    加入学术空间
    2Sex Differences in Glucagon-Like Peptide-1 Signalling and the Implications for Alzheimer’s Disease: A Narrative Review
    Serene Lee, Esha Purewal,Natalie Rasgon, Angela Kwan, Christine E. Dri,Roger Ho,Roger S. McIntyre

    Abstract Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and is the most common form of dementia. Women are differentially affected by AD, and several sex-specific mechanisms have been explored, including hormonal differences (eg, estrogen). Glucagon-like peptide-1 (GLP-1R) are located in brain regions implicated in the pathogenesis of AD and shows preliminary evidence of modulating sex-specific pathways that may underlie differential disease risk and progression. Herein, we synthesize the extant literature on the mechanisms of GLP-1 in neurobiological systems relevant to AD pathology. Metabolic signalling (eg, GLP-1, insulin) intersects with known sex-specific pathways hypothesized to subserve AD progression in women. The preceding effects may be attributable to the disruption of estrogen signalling during the postmenopausal period, which impairs hippocampal insulin receptor function and exacerbates mitochondrial dysfunction. In addition, these mechanisms provide an explanation for AD comorbidities (eg, type 2 diabetes mellitus [T2DM]). The multidimensional effects demonstrated in GLP-1 paradigms provide a compelling rationale for further investigation of the role of metabolic signalling on sex-specific alterations in AD. Evidence across preclinical and early clinical studies suggests that GLP-1RAs may differentially influence neurobiological pathways implicated in AD pathogenesis, particularly those that interact with hormonal and metabolic systems.

    2026
    引用
    AI阅读
    加入学术空间
    3Improving Care for Patients with Functional Neurological Symptom Disorder (FND): Clinical Pearls for Front Line Providers
    Alison Buchholz, Jason Chua, Mackenzie Cervenka, Eva Keatley

    Abstract Our understanding of functional neurological symptom disorder (FND) has evolved more quickly than dissemination of our progressed knowledge. Healthcare providers remain suboptimally educated about and trained in FND-informed care. As a result, patients continue to have harmful interactions with the healthcare system around FND, often beginning with poorly established and delivered diagnosis and uninformed or otherwise lacking treatment planning. This results in iatrogenic harm to patients and misuse of healthcare resources. Appreciating this, providers repeatedly request guidance on FND-informed diagnosis and treatment. This article serves to provide guidance on FND diagnosis and treatment planning for healthcare providers and patients.

    2026
    引用
    AI阅读
    加入学术空间
    4Biochemical Correlates of Social Anxiety in Subjects with Autism Spectrum Conditions
    Benedetta Nardi,Lionella Palego,Chiara Bonelli,Valeria Tognini,Cristiana Pronesti, Matteo Pioltino,Gabriele Massimetti,Stefano Pini,Alessandro Saba,Laura Betti,Gino Giannaccini,Lilliana Dell'Osso,

    Abstract Background Social anxiety disorder (SAD) is a common and debilitating condition marked by intense fear of negative evaluation in social situations. It often co-occurs with other psychiatric disorders, and in particular Autism Spectrum Disorder (ASD). The exact cause of SAD is unclear, though biological, environmental, and genetic factors are believed to contribute. Recent research highlights the involvement of neuropeptides, neurohormones, and immune system components in SAD development, suggesting complex interactions between psychological and biological factors, with a growing focus on inflammation’s role. This study aimed to investigate potential biochemical correlates of SAD in individuals with ASD, their first-degree relatives (BAP group), and healthy controls (HCs), focusing on inflammatory markers, neuropeptides, and growth factors. Methods Twenty-four adults with ASD, their relatives, and HCs, for a total of 72 participants, were assessed. Biochemical parameters were analyzed using enzyme-linked immunosorbent assays (ELISA), and social anxiety symptoms were evaluated via the Social Phobia Spectrum—Self Report (SHY-SR) questionnaire. Results Individuals with ASD exhibited significantly higher SHY-SR scores compared to the BAP and HCs. Subjects in the ASD group tended to make greater use of anxiolytics in order to improve their social interaction skills. Additionally, a specific pattern of correlation and association was found between biochemical variables and specific SAD symptoms, suggesting a potential role of inflammatory pathways in SAD pathophysiology. Conclusions Our results confirm the presence of greater social phobic symptoms in subjects with ASD, and support the hypothesis of a role of the inflammatory cascade in the maintenance of the disorder.

    2026
    引用
    AI阅读
    加入学术空间
    5Pharmacotherapy for Social Anxiety Disorder: an Evidence-Based Treatment Review
    Jeffrey Robert Strawn,Stephen M. Stahl,Azmi Nasser,Andrew J. Cutler,Márcio Bernik

    Abstract Social anxiety disorder (SAD) is a common and often chronic psychiatric illness characterized by persistent fear of social or performance situations and associated functional impairment and avoidance. Although multiple pharmacologic treatments have been studied, questions remain regarding optimal sequencing of therapies, long-term treatment strategies, and the management of partial or treatment-resistant illness. This narrative review synthesizes the evidence for pharmacologic treatments for SAD across medication classes, including antidepressants, benzodiazepines, monoamine oxidase inhibitors, GABA-related agents, second-generation antipsychotics, and emerging interventions. It also examines as-needed (PRN) interventions and steroid-based approaches, deprescribing and proposes a definition of treatment-resistant SAD. Randomized controlled trials, open-label studies, and guideline recommendations were reviewed to provide a framework for pharmacologic decision-making. Selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) remain the best-supported first-line pharmacotherapies for SAD. Evidence supports switching within or across antidepressant classes and integrating pharmacotherapy with behavioral interventions in patients with incomplete response. Additional treatments, including benzodiazepines, monoamine oxidase inhibitors, pregabalin, and selected augmentation strategies, may be considered for patients with persistent symptoms, although the evidence base is more limited. Data regarding long-term outcomes and treatment-resistant populations remain relatively sparse. While serotonergic antidepressants remain the cornerstone of treatment, optimal management requires individualized sequencing of therapies, integration with behavioral interventions, and consideration of alternative mechanisms in patients with incomplete response. Future studies should prioritize comparative effectiveness, long-term outcomes, and interventions for treatment-resistant SAD.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 4514 篇论文

    高被引作者

    作者引用发文
    Dan Stein392286
    Stephen M. Stahl282190
    Eric Hollander2643134
    Michael Edward Thase222121
    Donatella Marazziti173298
    Larry J. Siever15106
    Dell'Osso Liliana140953
    Stephen M. Stahl140237
    Thomas L. Schwenk13681
    Rg Marek13681

    高产作者

    作者引用发文
    Eric Hollander2643134
    Donatella Marazziti173298
    Roger McIntyre118792
    Stephen M. Stahl282190
    Dan Stein392286
    Jack Gorman66564
    Joseph Zohar85853
    Dell'Osso Liliana140953
    Christopher Naccari23153
    José Ralat151

    相关期刊

    Archiv fur Psychiatrie und Nervenkrankheiten
    Journal of Clinical Psychiatry
    International clinical psychopharmacology
    The journal of ECT
    Bipolar Disorders
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
    International journal of psychiatry in clinical practice
    International Journal of Bipolar Disorders
    European Archives of Psychiatry and Clinical Neuroscience
    Psychiatric Clinics of North America